CanRisk tool combines polygenic scores and family history to identify elevated breast cancer risk in younger women
A Cancer Research UK feature examines how the CanRisk programme uses germline variant data, polygenic scores, and questionnaire-based risk factors to stratify breast cancer risk beyond BRCA1 and BRCA2.
Cancer Research UK has published an overview of the CanRisk programme, a risk-stratification initiative developed by researchers including those at the University of Cambridge. CanRisk uses a validated computational tool — the BOADICEA model — that integrates rare pathogenic variants in genes such as BRCA1, BRCA2, PALB2, ATM, and CHEK2 with polygenic risk scores, hormonal and reproductive factors, imaging data, and family history to estimate an individual's lifetime risk of breast and ovarian cancer.
The feature focuses specifically on the programme's potential to identify younger women whose risk is substantially elevated but who would not be flagged under criteria that consider BRCA1 and BRCA2 alone. Researchers have argued that broadening the genetic panel and integrating polygenic risk scores could allow risk-stratified surveillance to be offered earlier and more equitably.
From an educational standpoint, the piece illustrates how modern breast cancer risk models differ structurally from earlier single-gene frameworks: they are probabilistic, multi-input, and explicitly designed to handle uncertainty in variant classification. The CanRisk web tool is available to clinicians for research and educational purposes. Published guidance from NHS England and NICE describes criteria under which risk assessment and surveillance may be considered for women with elevated familial or genetic risk; readers are directed to those sources for current clinical frameworks.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Researchers and clinicians in the UK have been developing a computer programme called CanRisk, which uses information about a person's genes, family history, and other factors to estimate the likelihood of developing breast cancer. Unlike older approaches that focused mainly on faults in the BRCA1 and BRCA2 genes, CanRisk also takes into account many smaller genetic differences — sometimes called a polygenic risk score — that together can add up to a meaningful change in risk. The aim is to identify younger women who may have a higher-than-average risk, so that research can explore whether earlier or more tailored monitoring might be beneficial. This is an area of active research rather than a settled clinical pathway. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Cancer Research UK · 2026-10-05BRCA and beyond: finding younger women with a higher risk of breast cancer